Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study

Yıl: 2012 Cilt: 18 Sayı: 1 Sayfa Aralığı: 1 - 7 Metin Dili: Diğer İndeks Tarihi: 29-07-2022

Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study

Öz:
Amaç: BONCURE (Mevcut Bisfosfonat Kullanıcıları İçin Bonviva Bölgesel Avrupa Çalışması) ile daha önce günlük veya haftalık alendronat veya risendronat alan postmenopozal osteoporozu olan kadınlarda aylık ibandronat için hasta tercihinin değerlendirilmesi amaçlandı. Gereç ve Yöntemler: Bu prospektif, açık-etiketli çalışma, iki ardışık aşamadan oluşmuştur: A (tarama) ve B (tedavi) aşaması. A aşamasına kaydolan hastalar Aday Kimlik Anketi (CIQ) tamamladı. B aşamasında, Osteoporoz Hasta Memnuniyeti Anketi (OPSAT Q) tamamladıktan sonra, hastalar 6 ay boyunca aylık oral 150 mg ibandronat aldı. Tedaviden sonra, hastalar OPSAT-Q ve Tercihi Anketi tamamladı. Bulgular: Türkiye’den 223 hasta (yaş ortalaması 63,7±9,51) A aşamasına dahil edildi. Bunların arasında, 103’ü (%46,2) en az bir CIQ sorusunu "EVET" yanıtladı. Ortalama bileşik OPSAT-Q alan puanları; kolaylık (ortalama değişiklik, 15,3±17,7 puan), yaşam kalitesi (10,4±20,4 puan), genel memnuniyet (11,9±22,7 puan) ve yan etkiler (3,3±18,8 puan) için arttı. Altıncı ayda 177 hasta (%92,7) bir kez aylık doz programını tercih etti ve %99,0’u çalışma tedavisi ile uyumlu (≥%80) idi. Otuz hasta (%15,6) çoğunlukla gastrointestinal olan hafif ve orta şiddette advers olay yaşadı. Sonuç: Postmenopozal osteoporozu olan kadınlar, günlük veya haftalık bifosfonat tedavisine göre aylık ibandronatı daha çok tercih etmekte ve bu tedavi ile daha memnun ve uyumlu olmaktadır. (Türk Os te opo roz Dergisi 2012;18:1-7)
Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Günlük veya haftalık alendronat veya risendronat alan postmenopozal osteoporozlu kadınlarda aylık ibandronat için hasta tercihinin değerlendirildiği açık- etiketli, prospektif, çok-merkezi, iki-aşamalı çalışma-BONCURE: Türkiye alt-çalışması

Öz:
Aim: BONCURE (Bonviva for Current Bisphosphonate Users Regional European Trial), aimed to evaluate patient preference with monthly ibandronate in women with postmenopausal osteoporosis who previously received daily or weekly alendronate or risendronate. Materials and Methods: This prospective, open-label study consisted of two sequential stages, Part A (screening) and Part B (treatment). Patients enrolled into Part A completed the Candidate Identification Questionnaire (CIQ). In Part B, after completing the Osteoporosis Patient Satisfaction Questionnaire (OPSATQ), patients received monthly oral ibandronate 150 mg for 6 months. Following treatment, patients completed the OPSAT-Q and Preference Questionnaire. Results: A total of 223 patients (mean age, 63.7±9.51 years) were enrolled in Part A from Turkey. Among them, 103 (46.2%) answered “YES” to at least one CIQ question. The mean composite OPSAT-Q domain scores increased for convenience (mean change, 15.3±17.7 points), quality of life (10.4±20.4 points), overall satisfaction (11.9±22.7 points), and side effects (3.3±18.8 points). At month 6, 177 subjects (92.7%) preferred once-monthly dosing schedule and 99.0% were compliant (≥80%) with study treatment. Thirty (15.6%) subjects experienced mild to moderate adverse events, mostly gastrointestinal. Conclusion: Postmenopausal women with osteoporosis prefer and are more satisfied and compliant with monthly dosing of ibandronate than daily or weekly bisphosphonate treatment. (Turkish Journal of Osteoporosis 2012;18:1-7)
Anahtar Kelime:

Konular: Genel ve Dahili Tıp
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
  • 2. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
  • 3. Papapoulos SE. Bisphosphonates in the management of postmenopausal osteoporosis. In: Marus R, Osteoporosis, Second Edition, Vol.2: 631- 650; 2001.
  • 4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11.
  • 5. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 2008;23:1569-75.
  • 6. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22.
  • 7. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8.
  • 8. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
  • 9. Sclar DA. Improving medication compliance: a review of selected issues. Clin Ther 1991;13:436-40; discussion 5.
  • 10. Reginster JY, Rabenda V. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Clin Interv Aging 2006;1:415-23.
  • 11. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35; discussion 6.
  • 12. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871-86.
  • 13. Payer J, Cierny D, Killinger Z, Sulkova I, Behuliak M, Celec P. Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates--the VIVA II study. J Int Med Res 2009;37:1225-9.
  • 14. Lewiecki EM. Long dosing intervals in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 2007;23:2617-25.
  • 15. Reid DM. Once-monthly dosing: an effective step forward. Bone 2006;38:S18-22.
  • 16. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
  • 17. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61.
  • 18. Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008;27:955-60.
  • 19. Bonnick SL, Silverman S, Tanner SB, Martens M, Bachmann G, Kohles JD, et al. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) 2009;18:935-43.
  • 20. Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, et al. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 2009;28:321-6.
  • 21. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-10.
  • 22. Flood EM, Beusterien KM, Green H, Shikiar R, Baran RW, Amonkar MM, et al. Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 2006;4:42.
  • 23. de Oliveira Ferreira N, Arthuso M, da Silva R, Pedro AO, Neto AM, Costa- Paiva L. Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36. Maturitas 2009;62:85-90.
  • 24. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001;44:2611-9.
  • 25. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903.
APA eskiyurt n, İRDESEL J, SEPİCİ V, UĞURLU H, Kirazlı Y, Ardic Yukruk F, BÜTÜN B, AKYUZ G, Cerrahoglu L, ŞENDUR Ö, YALÇIN P, Oncel H, SARIDOĞAN F, SARPEL T, Tosun M, Gokce Kutsal F, ŞENEL K, Gursoy S, CANTÜRK F, DEMIR H, ozdener f, ÖNCEL H (2012). Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. , 1 - 7.
Chicago eskiyurt nurten,İRDESEL Jale,SEPİCİ Vesile,UĞURLU Hatice,Kirazlı Yeşim,Ardic Yukruk Fisun,BÜTÜN Bülent,AKYUZ GULSEREN,Cerrahoglu Lale,ŞENDUR Ömer Faruk,YALÇIN Peyman,Oncel Hatice Sema,SARIDOĞAN FEVZİYE MERİH,SARPEL TUNAY,Tosun Mehmet,Gokce Kutsal F. Yesim,ŞENEL Kazım,Gursoy Savas,CANTÜRK Ferhan,DEMIR HÜSEYIN,ozdener fatih,ÖNCEL Hakan Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. (2012): 1 - 7.
MLA eskiyurt nurten,İRDESEL Jale,SEPİCİ Vesile,UĞURLU Hatice,Kirazlı Yeşim,Ardic Yukruk Fisun,BÜTÜN Bülent,AKYUZ GULSEREN,Cerrahoglu Lale,ŞENDUR Ömer Faruk,YALÇIN Peyman,Oncel Hatice Sema,SARIDOĞAN FEVZİYE MERİH,SARPEL TUNAY,Tosun Mehmet,Gokce Kutsal F. Yesim,ŞENEL Kazım,Gursoy Savas,CANTÜRK Ferhan,DEMIR HÜSEYIN,ozdener fatih,ÖNCEL Hakan Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. , 2012, ss.1 - 7.
AMA eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. . 2012; 1 - 7.
Vancouver eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. . 2012; 1 - 7.
IEEE eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H "Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study." , ss.1 - 7, 2012.
ISNAD eskiyurt, nurten vd. "Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study". (2012), 1-7.
APA eskiyurt n, İRDESEL J, SEPİCİ V, UĞURLU H, Kirazlı Y, Ardic Yukruk F, BÜTÜN B, AKYUZ G, Cerrahoglu L, ŞENDUR Ö, YALÇIN P, Oncel H, SARIDOĞAN F, SARPEL T, Tosun M, Gokce Kutsal F, ŞENEL K, Gursoy S, CANTÜRK F, DEMIR H, ozdener f, ÖNCEL H (2012). Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. Türk Osteoporoz Dergisi, 18(1), 1 - 7.
Chicago eskiyurt nurten,İRDESEL Jale,SEPİCİ Vesile,UĞURLU Hatice,Kirazlı Yeşim,Ardic Yukruk Fisun,BÜTÜN Bülent,AKYUZ GULSEREN,Cerrahoglu Lale,ŞENDUR Ömer Faruk,YALÇIN Peyman,Oncel Hatice Sema,SARIDOĞAN FEVZİYE MERİH,SARPEL TUNAY,Tosun Mehmet,Gokce Kutsal F. Yesim,ŞENEL Kazım,Gursoy Savas,CANTÜRK Ferhan,DEMIR HÜSEYIN,ozdener fatih,ÖNCEL Hakan Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. Türk Osteoporoz Dergisi 18, no.1 (2012): 1 - 7.
MLA eskiyurt nurten,İRDESEL Jale,SEPİCİ Vesile,UĞURLU Hatice,Kirazlı Yeşim,Ardic Yukruk Fisun,BÜTÜN Bülent,AKYUZ GULSEREN,Cerrahoglu Lale,ŞENDUR Ömer Faruk,YALÇIN Peyman,Oncel Hatice Sema,SARIDOĞAN FEVZİYE MERİH,SARPEL TUNAY,Tosun Mehmet,Gokce Kutsal F. Yesim,ŞENEL Kazım,Gursoy Savas,CANTÜRK Ferhan,DEMIR HÜSEYIN,ozdener fatih,ÖNCEL Hakan Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. Türk Osteoporoz Dergisi, vol.18, no.1, 2012, ss.1 - 7.
AMA eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. Türk Osteoporoz Dergisi. 2012; 18(1): 1 - 7.
Vancouver eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study. Türk Osteoporoz Dergisi. 2012; 18(1): 1 - 7.
IEEE eskiyurt n,İRDESEL J,SEPİCİ V,UĞURLU H,Kirazlı Y,Ardic Yukruk F,BÜTÜN B,AKYUZ G,Cerrahoglu L,ŞENDUR Ö,YALÇIN P,Oncel H,SARIDOĞAN F,SARPEL T,Tosun M,Gokce Kutsal F,ŞENEL K,Gursoy S,CANTÜRK F,DEMIR H,ozdener f,ÖNCEL H "Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study." Türk Osteoporoz Dergisi, 18, ss.1 - 7, 2012.
ISNAD eskiyurt, nurten vd. "Open, prospective, Multi-Center, Two-Part study of patient preference with monthly ibandronate therapy in women with postmenopausal osteoporosis switched from daily or weekly alendronate or risendronate-BONCURE: Results of Turkish sub-study". Türk Osteoporoz Dergisi 18/1 (2012), 1-7.